Abstract
Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 363-387 |
| Number of pages | 25 |
| Journal | Veterinary Sciences |
| Volume | 2 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2015 |
Bibliographical note
Publisher Copyright:© 2015 by the authors.
Keywords
- Adaptive immunity
- Antibodies
- Fas ligand
- Immunization
- T-lymphocytes
- Virotherapy
